Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGFV3Z)

Drug Name
Nizatidine Drug Info
Synonyms
Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
Indication
Disease Entry ICD 11 Status REF
Acid-reflux disorder DA22 Approved [1]
Gastric ulcer DA60 Approved [2]
Peptic esophagitis Approved [2]
Peptic ulcer DA61 Approved [2]
Therapeutic Class
Antiulcer Agents
Cross-matching ID
PubChem CID
3033637
ChEBI ID
CHEBI:7601
CAS Number
CAS 76963-41-2
TTD Drug ID
DMGFV3Z
VARIDT Drug ID
DR00263
INTEDE Drug ID
DR2187
ACDINA Drug ID
D00477

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Histamine H2 receptor (H2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [7]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [8]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [8]
Betazole DMUFGAY Gastric secretory disorder DD90 Approved [9]
Ebrotidine DMV5KR3 Duodenal ulcer DA63 Withdrawn from market [10]
Pibutidine DMXSTRM Ulcerative colitis DD71 Discontinued in Phase 3 [11]
Osutidine DMN7TL8 Duodenal ulcer DA63 Discontinued in Phase 3 [12]
KU-1257 DMZMFX6 Duodenal ulcer DA63 Discontinued in Phase 3 [13]
Lavoltidine DMTY5VE Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [14]
IGN-2098 DMU4N1O Duodenal ulcer DA63 Discontinued in Phase 2 [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [16]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [17]
Methotrexate DM2TEOL Anterior urethra cancer Approved [18]
Folic Acid DMEMBJC Colorectal carcinoma Approved [19]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [18]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [18]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [20]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [18]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [21]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic cation transporter 1 (SLC22A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [23]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [24]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [25]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [26]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [16]
Verapamil DMA7PEW Angina pectoris BA40 Approved [27]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [28]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [29]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [30]
Propranolol DM79NTF Angina pectoris BA40 Approved [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Calcitonin (CALCA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [6]
Fructose DM43AN2 Vomiting MD90 Approved [32]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [33]
Panobinostat DM58WKG Chronic graft versus host disease Approved [34]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [35]
Folic Acid DMEMBJC Colorectal carcinoma Approved [36]
Capsaicin DMGMF6V Back pain ME84.Z Approved [37]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [38]
Azacitidine DMTA5OE Acute myelogenous leukaemia 2A41 Approved [39]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protachykinin-1 (TAC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [6]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [41]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [42]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [43]
Panobinostat DM58WKG Chronic graft versus host disease Approved [34]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [44]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [45]
Capsaicin DMGMF6V Back pain ME84.Z Approved [46]
Sodium lauryl sulfate DMLJ634 Constipation DD91.1 Approved [47]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [48]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H2 receptor (H2R) TTQHJ1K HRH2_HUMAN Antagonist [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [4]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Calcitonin (CALCA) OTZ11LHB CALC_HUMAN Gene/Protein Processing [6]
Protachykinin-1 (TAC1) OTM842YW TKN1_HUMAN Gene/Protein Processing [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7248).
2 Nizatidine FDA Label
3 Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
4 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
5 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00585)
6 Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. J Pharm Pharmacol. 2002 Nov;54(11):1559-63. doi: 10.1211/002235702117.
7 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
8 Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
9 Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
10 Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
11 Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
12 Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
13 Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
14 New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
15 Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80.
16 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
17 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
18 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
19 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
20 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
21 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
22 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
23 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
24 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
25 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
26 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
27 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
28 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
29 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
30 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
31 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
32 Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
33 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
34 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
35 The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
36 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
37 Transient receptor potential vanilloid 1-mediated expression and secretion of endothelial cell-derived calcitonin gene-related peptide. Regul Pept. 2008 Oct 9;150(1-3):66-72. doi: 10.1016/j.regpep.2008.05.007. Epub 2008 Jun 3.
38 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
39 Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693.
40 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
41 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
42 Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee. Rheumatology (Oxford). 2006 Jun;45(6):765-70. doi: 10.1093/rheumatology/kei253. Epub 2006 Jan 31.
43 Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur J Neurosci. 2005 Mar;21(6):1712-8. doi: 10.1111/j.1460-9568.2005.04002.x.
44 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
45 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
46 Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004 Mar;13(3):129-39. doi: 10.1111/j.0906-6705.2004.0178.x.
47 CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
48 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.